Published in Oncogene on August 10, 2015
The Role of PIAS SUMO E3-Ligases in Cancer. Cancer Res (2017) 0.75
Linking DNA Damage and Hormone Signaling Pathways in Cancer. Trends Endocrinol Metab (2016) 0.75
Multi-label ℓ2-regularized logistic regression for predicting activation/inhibition relationships in human protein-protein interaction networks. Sci Rep (2016) 0.75
Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome. Nucleic Acids Res (2016) 0.75
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res (2012) 5.50
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature (2009) 4.30
Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol Cell (2001) 3.56
Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16
Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A (2002) 2.85
Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci U S A (2000) 2.79
PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci (2009) 1.94
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer (2013) 1.55
PIAS proteins and transcriptional regulation--more than just SUMO E3 ligases? Genes Dev (2006) 1.50
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol (2012) 1.48
Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene (2001) 1.48
PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Mol Cell Biol (2004) 1.33
ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol (2011) 1.31
Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med (2002) 1.25
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood (2009) 1.18
Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci (2013) 1.16
Androgen modulation of coregulator expression in prostate cancer cells. Mol Endocrinol (2009) 1.14
Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res (2001) 1.13
Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis. Mol Cell Biol (2011) 1.12
Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res (2009) 1.09
Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus. Mol Cell Biol (2012) 1.04
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol (2012) 1.02
Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res (2013) 0.99
Anterior gradient 2 and 3--two prototype androgen-responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells. FEBS J (2013) 0.94
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate (2014) 0.92
The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate (2006) 0.90
SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. Nucleic Acids Res (2014) 0.90
Activation of the SUMO modification system is required for the accumulation of RAD51 at sites of DNA damage. J Cell Sci (2013) 0.86
SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner. Nucleic Acids Res (2014) 0.86
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. Oncotarget (2014) 0.82
PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing. PLoS One (2014) 0.81
Latent hypothyreosis as a clinical biomarker for therapy response under abiraterone acetate therapy. Anticancer Res (2014) 0.77
PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia. Leukemia (2016) 0.80
Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract. Clin Epigenetics (2016) 0.75
The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma. Clin Transl Oncol (2020) 0.75